



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Reply, the Application of

HEINZ P. VOLLMERS, et al.

Group Art Unit: 1642

Application No.: 10/506,763

Examiner: Halvorson, Mark

Filed: May 12, 2005

Confirmation No.: 8912

For: NEOPLASM SPECIFIC ANTIBODIES AND USES THEREOF

INFORMATION DISCLOSURE STATEMENT

03/16/2007 IPOLITE1 00000059 033975 10506763

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

01 FC:1806 180.00 DA

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Applicants respectfully request the Examiner return an initialed copy of the enclosed Form PTO-1449 to Applicants with the next Office communication to indicate that the reference(s) has been considered, per MPEP § 609.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.


Please charge Deposit Account 033975 in the amount of \$180.00 in payment of the fee under 37 CFR 1.17(p). Please credit or debit Deposit Account 033975 as needed to ensure consideration of the disclosed information.

A copy of the International Search Report is attached for the Examiner's information. According to the Notification of Acceptance in this file, copies of the references are already in the U.S. Patent Office file. For convenience, copies of these references are also attached.

Please note that for Publication No. WO 02/02641 A1, identified as reference number "WR" on Form PTO-1449, a compact disc (CD) that has the sequence listing in compliance with 37 C.F.R. 1.52(e) is enclosed.

Respectfully Submitted,

PILLSBURY WINTHROP SHAW PITTMAN LLP


A handwritten signature in black ink, appearing to read 'Robert M. Bedgood', is written over a horizontal line.

Robert M. Bedgood

Registration Number 43488

Customer Number: 27500

Date: March 15, 2007
Telephone: (619) 234-5000
Facsimile: (858) 509-4010
11682 El Camino Real
Suite 200
San Diego, CA 92130-2092



PTO/SB/17 (01-06)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

Pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL
For FY 2006☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

Complete if Known

Application Number	10/506,763
Filing Date	May 12, 2005
First Named Inventor	Heinz P. Vollmers
Examiner Name	Halvorson, Mark
Art Unit	1642
Attorney Docket No.	015065-0358749

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Account Deposit Account Number: 033975 Deposit Account Name: PILLSBURY WINTHROP SHAW PITTMAN LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION (All the fees below are due upon filing or may be subject to a surcharge.)**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES**Fee Description**

Each claim over 20 (including Reissues)
Each independent claim over 3 (including Reissues)
Multiple dependent claims

Small Entity	
Fee (\$)	Fee (\$)
50	25
200	100
360	180
Multiple Dependent Claims	
Fee (\$)	Fee Paid (\$)

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
--------------	--------------	----------	---------------

- 20 or HP = _____ x _____ = _____

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
---------------	--------------	----------	---------------

- 3 or HP = _____ x _____ = _____

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
--------------	--------------	--------------------------------------------------	----------	---------------

- 100 = _____ / 50 = _____ (round up to a whole number) x 125.00 = 0.00

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): IDS

Fees Paid (\$)

180.00

SUBMITTED BY

Signature

Registration No.
(Attorney/Agent)

43488

Telephone

858.509.4065

Name (Print/Type)

Robert Bedgood

Date

March 15, 2007

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

015065-0358749

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Vollmers, et al.

Appln. No.: 10/506,763

Filing Date: May 12, 2005

Date: March 15, 2007

P
a
g
e

1

of

5

Examiner: Halvorson, Mark

Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR						
	BR	2005/0123571 A1	06/2005	Rossini, et al.	424	277.1	
	CR	5,610,280	03/1997	Brandt, et al.	530	387.5	
	DR	5,639,863	06/1997	Dan	530	388.8	
	ER	5,763,224	06/1998	Caras, et al.	435	69.6	
	FR	6,677,442 B1	1/2004	Wang, et al.	536	23.2	
	GR	6,995,240 B1	02/2006	Panayi, et al.	530	350	
	HR	7,049,132 B1	05/2006	Lee	435	320.1	
	IR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
	JR								
	KR	41 07 154 A1	04/1992	DE	Brandt, et al. (German)				
	LR	102 30 516 A1	01/2004	DE	Müller-Hermelink, et al.				
	MR	692 12 671 T2	03/1997	DE	Weiss, et al. (German)				
	NR	692 29 110 T2	11/1999	DE	Gram, et al. (German)				
	OR	695 27 975 T2	03/2003	DE	Ellis, et al. (German)				
	PR	1 106 183 A2	06/2001	EP	Fendly				
	QR	1 106 183 A3	06/2001	EP	Fendly				

	RR	1 141 019 B1	04/2004	EP	Vollmers et al. (German)					
	SR	00/37489 A2	06/2000	WO	Vollmers et al. (German)					
	TR	00/37489 A3	06/2000	WO	Vollmers et al. (German)					
	UR	01/62932 A1	08/2001	WO	Deshpande, et al.					
	VR	01/83560 A1	11/2001	WO	Zhou, et al.					
	WR	02/02641 A1	01/2002	WO	Cambridge Antibody Tech., Vaughn Tristan					
	XR	02/084277 A1	10/2002	WO	Luo					
	YR	02/12502 A2	02/2002	WO	Giles-Komar, et al.					
	ZR	03/011907 A3	02/2003	WO	Muller-Hermelink et al.					
	AAR	2003/076472 A2	09/2003	WO	Vollmers, et al.					
	BBR	2003/076472 A3	09/2003	WO	Vollmers, et al.					
	CCR	2004/005351 A2	01/2004	WO	Mueller- Hermelink, et al.					
	DDR	2004/020999A1	03/2004	WO	Arap, et al.					
	EER	2004/081027 A2	09/2004	WO	Mueller- Hermelink et al.					
	FFR	2004/081027 A3	09/2004	WO	Mueller- Hermelink et al.					
	GGR	2005/001052 A2	01/2005	WO	Rossini, et al.					
	HHR	2005/045428 A2	05/2005	WO	Lee, et al.					
	IIR	2005/047332 A1	05/2005	WO	Vollmers, et al.					
	JJR	2005/065418 A2	07/2005	WO	Pasqualini, et al.					
	KKR	2005/085862 A1	09/2005	WO	Charles, et al.					
	LLR	2005/092922 A2	10/2005	WO	Vollmers et al.					
	MMR	2005/092922 A3	10/2005	WO	Vollmers et al.					
	NNR	2005/094159 A2	10/2005	WO	Vollmers et al.					
	OOR	97/02479	01/1997	WO	Garen					
	PPR	97/13844 A1	04/1997	WO	Thomson et al.					
	QQR	99/28461	06/1999	WO	Noteborn, et al.	(equivalent to CA 2,312,007 06/2000)				
	RRR	99/53051	10/1999	WO	Dumas Milne Edwards, et al					
	SSR	99/65935 A2	12/1999	WO	Chiodi					
	TTR									
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)										
	UUR									

	VVR					
	WWR	Berger, C.L., et al., A Lymphocyte Cell Surface Heat Shock Protein Homologous to the Endoplasmic Reticulum Chaperone, Immunoglobulin Heavy Chain Binding Protein BIP, Int. J. Cancer, 71:1077-1085 (1997)				
	XXR	Bjorge et al., Complement-Regulatory Proteins in Ovarian Malignancies, Int. J. Cancer, 70:14-25 (1997)				
	YYR	Brändlein et al., "Natural IgM Antibodies and Immunosurveillance Mechanisms Against Epithelial Cancer Cells in Humans," Cancer Research, 63: 7995-8005, 15 November 2003.				
	ZZR	Brändlein et al., Characterization of Five New Fully Human Monoclonal IgM Antibodies Isolated from Carcinoma Patients, Proceedings of the Annual Meeting of the American Association for Cancer Research 43:970, March 2002 (Abstract)				
	AAAR	Brändlein et al., Human Monoclonal IgM Antibodies with Apoptotic Activity isolated from Cancer Patients, Human Antibodies 11:107-119, 2002				
	BBBR	Brändlein, S., et al., CFR-1 Receptor as Target for Tumor-specific Apoptosis Induced by the Natural Human Monoclonal Antibody PAM-1, Oncology Reports, 11:777-784 (2004)				
	CCCR	Brändlein, S., et al., Cysteine-rich Fibroblast Growth Factor Receptor 1, a New Marker for Precancerous Epithelial Lesions Defined by the Human Monoclonal Antibody PAM-1, Cancer Research, 63:2052-2061 (2003)				
	DDDR	Brändlein, S., et al., PAM-1, a Natural Human IgM Antibody as New Tool for Detection of Breast and Prostate Precursors, Human Antibodies, 13:97-104 (2004)				
	EEER	Chen, G., et al., Protein Profiles Associated With Survival in Lung Adenocarcinoma, www.pnas.org/cgi/doi/10.1073/pnas.2233850100 pp. 1-6 (2003)				
	FFFR	Database entry AAB02178 dated June 11, 1996				
	GGGR	Faller et al., HAB-1, a New Heteromyeloma for Continuous Production of Human Monoclonal Antibodies, Br. J. Cancer 62:595-598 (1990)				
	HHHR	Gonatas et al., MG-160, A Membrane Sialoglycoprotein of the Medial Cisternae of the Rat Golgi Apparatus, Binds Basic Fibroblast Growth Factor and Exhibits a High level of Sequence Identity to a Chicken Fibroblast Growth Factor Receptor, J. Cell Science 108:457-467, 1995.				
	IIIR	Grossman, H.B., Natural Antibody to a Human Bladder Carcinoma Cell Line, Cancer Immunol. Immunother. 13:89-92 (1982)				
	JJJR	Hensel et al., A New Variant of Cystein-Rich FGF Receptor (CFR-1) Specifically Expressed on Tumor Cells, Proceedings of the American Association for Cancer Research 41:698 (abstract 4438), March 2000.				
	KKKR	Hensel et al., A Novel Proliferation-associated Variant of CFR-1 Defined by a Human Monoclonal Antibody, Laboratory Investigation 81:1097-1108, 2001.				
	LLLR	Hensel et al., Characterization of Glycosylphosphatidylinositol-linked Molecule CD55/Decay-accelerating Factor as the Receptor for Antibody SC-1-induced Apoptosis, Cancer Research 59:5299-5306, 1999.				

	MMMR	Hensel et al., Mitogenic Autoantibodies in Helicobacter pylori-Associated Stomach Cancerogenesis, International Journal of Cancer 81:229-235, 1999.				
	NNNR	Hensel, F., et al., "Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1-induced apoptosis", Laboratory Investigation, 81(11):1553-1563 (2001)				
	OOOR	Huang et al., Sulindac Sulfide-induced Apoptosis Involves Death Receptor 5 and the Caspase 8-dependent Pathway in Human Colon and Prostate Cancer Cells, Cancer Research 61:6918-6924 (2001)				
	PPPR	Jamora, C., et al., Inhibition of Tumor Progression by Suppression of Stress Protein GRP78/BiP Induction in Fibrosarcoma B/C10ME, Proc. Natl. Acad. Sci. USA, 93:7690-7694 (1996)				
	QQQR	Jansson, et al., The Human Repertoire of Antibody Specificities Against Thomsen-Friedenreich and TN-carcinoma-associated antigens as defined by Monoclonal Antibodies, Cancer Immunology 34:294-298, 1992.				
	RRRR	Kamitani, H., et al., Expression of 15-Lipoxygenase by Human Colorectal Carcinoma Caco-2 Cells During Apoptosis and Cell Differentiation, The Journal of Biological Chemistry, 273(34):21569-21577 (1998)				
	SSSR	Liu et al., Towards Proteome-Wide Production of Monoclonal Antibody by Phage Display, J. Mol. Bio. 315:1063-1073 (2002)				
	TTTR	Mammalian Gene Collection (MGC) Program Team, "Generation and Initial Analysis of more than 15,000 Full-Length Human and Mouse cDNA Sequences" PNAS USA 99:16,899-16,903 (2002)				
	UUUR	Masatoshi, K., Antibody CDNA, Abstract JP Publication No. 09098786 0, 04/15/1997				
	VVVR	Meng et al., p53-Independent Upregulation of KILLER/DR5 TRAIL Receptor Expression by Glucocorticoids and Interferon- γ , Experimental Cell Research 262:154-169 (2001)				
	WWWR	Mintz, P.J., et al., Fingerprinting the Circulating Repertoire of Antibodies from Cancer Patients, Nature Biotechnology, 21:57-63 (2003)				
	XXXR	Mourelatos et al., Cloning and Sequence Analysis of the Human MG160, a Fibroblast Growth Factor and E-Selectin Binding Membrane Sialoglycoprotein of the Golgi Apparatus, DNA Cell Biol. 12:1121-1128 (1996)				
	YYYY	Pfaff, M., et al., Human Monoclonal Antibody Against a Tissue Polypeptide Antigen-related Protein from a Patient with a Signet-Ring Cell Carcinoma of the Stomach, Cancer Research, 50:5192-5198 (1990)				
	ZZZR	Sato, K., et al., Immunotherapy Using Heat-Shock Protein Preparations of Leukemia Cells After Syngenic Bone Marrow Transplantation in Mice, Blood, 98(6):1852-1857 (2001)				
	AAAAR	Sugawara, S., et al., Suppression of Stress Protein GRP78 Induction in Tumor B/C10ME Eliminates Resistance to Cell Mediated Cytotoxicity, Cancer Research, 53:6001-6005 (1993)				
	BBBBR	Timmermann W., et al., Immuntherapie: ein Antikörper gegen Magenkrebs" Blick 1/1999, Artikel 6, internet page http://www.uni-wuerzburg.de/blick1999-1/991do6-t.html .				
	CCCCR	Vollmers et al., "Apoptosis of Stomach Carcinoma Cells Induced by a Human Monoclonal Antibody," Cancer 76:550-558 (1995).				

	DDDDR	Vollmers et al., "Human Monoclonal Antibodies from Stomach Carcinoma Patients React with <i>Helicobacter pylori</i> and Stimulate Stomach Cells <i>in vitro</i> ," Cancer 74:1525-1532, 1994.				
	EEEEER	Vollmers et al., "SC-1, a Functional Human Monoclonal Antibody against Autologous Stomach Carcinoma Cells," Cancer Res. 49:2471-2476, 1989.				
	FFFFR	Vollmers et al., Adjuvant Therapy for Gastric Adenocarcinoma with the Apoptosis-Inducing Human Monoclonal Antibody SC-1: First Clinical and Histopathological Results, Oncology Reports 5:549-552 (1998)				
	GGGGR	Vollmers, H.P., et al., Monoclonal Antibodies NORM-1 and NORM-2 Induce More Normal Behavior of Tumor Cells In Vitro and Reduce Tumor Growth In Vivo, Cell, 40:547-557 (1985).				
	HHHHR	Vollmers, P., et al., Tumor-Specific Apoptosis Induced by the Human Monoclonal Antibody SC-1: A New Therapeutical Approach for Stomach Cancer, Oncology Reports, 5:35-40 (1998)				
	IIIR	Wixler et al., "Identification of Novel Interaction Partners for the conserved membrane proximal region of alpha-integrin cytoplasmic domains," FEBS Letters vol. 445, 26 Feb 1999.				
	JJJJR					

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.